(Endpoints News) Gilead announced a global partnership that will bring its HIV pre-exposure prophylaxis drug lenacapavir ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress. PR Newswire.

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Extended oral antibiotic prophylaxis eliminated UTIs after robot-assisted radical cystectomy procedures. Prophylactic ...

The attack data in RAPIDe-3 have continued to accrue following the achievement of target enrollment in the study; we now estimate that our RAPIDe-3 topline data announcement will be in the fourth ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout ...

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress. News provided by.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress. News provided by.